- Home
- BCRX vs VRDN Comparison
BCRX vs VRDN Comparison
Compare BCRX & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCRX | VRDN |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BCRX | VRDN |
|---|---|---|
| Price | $9.86 | $24.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $20.82 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 3.1M | 1.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,186,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $12.55 | $279.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.00 | $13.18 |
| 52 Week High | $11.22 | $34.29 |
Technical Indicators
Market Signals| Indicator | BCRX | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 64.75 |
| Support Level | $8.79 | $21.62 |
| Resistance Level | $10.01 | $24.86 |
| Average True Range (ATR) | 0.44 | 0.83 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 38.21 | 71.60 |
Price Performance
Historical ComparisonAbout BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.